So for Pharma, what’s the value of R&D at all, when they could be undercut by what is basically a generic wrapped in “compound” coat for any product they develop.
We already have retatrutide in the UK, the public are buying it and using it. Assume we’ll have generic orforglipron and MariTide within the year.
Implications to the whole Pharma model are significant, no?
Very significant. I’m sure an FDA lawyer could tell us what the next steps are in the regulatory rung of escalation (I’ll bring one on)- but for now - compounding isn’t going anywhere w/o FDA enforcement (which, as I’ve argued, is unlikely to happen)
So for Pharma, what’s the value of R&D at all, when they could be undercut by what is basically a generic wrapped in “compound” coat for any product they develop.
We already have retatrutide in the UK, the public are buying it and using it. Assume we’ll have generic orforglipron and MariTide within the year.
Implications to the whole Pharma model are significant, no?
Very significant. I’m sure an FDA lawyer could tell us what the next steps are in the regulatory rung of escalation (I’ll bring one on)- but for now - compounding isn’t going anywhere w/o FDA enforcement (which, as I’ve argued, is unlikely to happen)
How long until someone tries it in another market (UK/EU) I wonder, now there’s a precedent… 🧐